Get the Stockscreener App
5.88
3.61%
-0.22
After Hours:
5.92
0.04
+0.68%
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low on Analyst Downgrade - MarketBeat
SG Americas Securities LLC Purchases Shares of 69,625 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $7.50 at Piper Sandler - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low Following Analyst Downgrade - MarketBeat
Oversold Conditions For Iovance Biotherapeutics (IOVA) - Nasdaq
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $23.00 Consensus Target Price from Analysts - MarketBeat
What's Wrong With Iovance Biotherapeutics Stock? - MSN
Institutional owners may consider drastic measures as Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) recent US$122m drop adds to long-term losses - Simply Wall St
(IOVA) Investment Report - Stock Traders Daily
Lion Biotechnologies, Inc. Appoints Michael T. Lotze, MD, as Chief Scientific Officer and Vice President of Research and Development - Marketscreener.com
Stifel maintains Buy on Iovance stock with $21 target - MSN
Where Will Iovance Biotherapeutics Be in 5 Years? - The Globe and Mail
Iovance Biotherapeutics (IOVA) Forecasts Strong Growth Due to Flagship Treatment - TipRanks
Iovance Biotherapeutics Inc to Host Earnings Call - ACCESS Newswire
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 12-Month LowWhat's Next? - MarketBeat
Peninsula biotech company sues insurance company to cover patients' injuries in clinical trials - The Business Journals
Insider Stock Buying Reaches US$48.3m On Iovance Biotherapeutics - Yahoo Finance
(IOVA) Technical Pivots with Risk Controls - Stock Traders Daily
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 1-Year LowHere's What Happened - MarketBeat
Cervical Cancer Market Expected to Experience Major Growth - openPR
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks - Insider Monkey
Is Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Yahoo Finance
1,746,877 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Purchased by Assenagon Asset Management S.A. - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics Awards 224,550 Stock Options to Expand Team with 41 New Hires - StockTitan
First Week of September 19th Options Trading For Iovance Biotherapeutics (IOVA) - Nasdaq
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 1-Year LowTime to Sell? - MarketBeat
IOVA Stock Touches 52-Week Low at $5.76 Amid Market Challenges - Investing.com
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week LowHere's Why - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet - Simply Wall St
How To Trade (IOVA) - Stock Traders Daily
Cancer Drug Maker Iovance Tumbles Toward Worst Week Since November, But Retail Feels Macro Selloff Overblown - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.8%Here's Why - MarketBeat
Iovance Biotherapeutics Shares Are Falling Today: What's Going On? - Benzinga
Immunotoxins Market Trends and Regional Business Opportunities, 2024-2034: Diphtheria Toxin-Based Immunotoxins Lead Revenue, Pseudomonas Exotoxins Show Rapid Growth Potential - GlobeNewswire Inc.
IOVA stock touches 52-week low at $7.05 amid market challenges - Investing.com
Iovance Biotherapeutics (IOVA) Surges on Positive Analyst Outloo - GuruFocus.com
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - MSN
Stifel maintains Buy on Iovance Biotherapeutics stock, optimistic on Amtagvi By Investing.com - Investing.com Canada
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):